We read with interest a report from Mani et al 1 characterizing demographic, immunologic, and clinical characteristics of a retrospectively collected cohort of patients with Kaposi's sarcoma (KS), most of whom were entered into the AIDS Malignancy Consortium studies. In a previous letter, 2 we prospectively identified 9 individuals who developed KS with at least 2 years of good immunologic control (CD4 counts >300 cells/mm 3 and undetectable viral load [VL]). Their KS has been persistent and indolent throughout follow-up. In Mani's group, 20 (22%) of 91 had KS despite CD4 >300 cells/mm 3 and undetectable VL; however only 7 (7%) of 90 had CD4 counts >300 cells/mm 3 and undetectable VL at the time of KS diagnosis. The duration of immunologic control before the diagnosis of KS is not clear from this description.
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In our description, we are drawing attention to that group similar to the 7 patients in Mani's report, who developed KS in the setting of concurrent, well-controlled HIV infection. While we and others agree that this is not a new phenomenon, it is perhaps more unusual than the prototypic patient who develops KS with lower CD4 counts and detectable VL only to resolve their KS with better immunologic control or develop persistent KS in spite of this. Making a distinction among these different groups may be important as they may be clinically and immunologically distinct. It is yet to be determined whether the characteristics that we described still persist in larger prospective studies. These characteristics include longer duration of HIV infection, older age at diagnosis of KS with higher CD4 counts, and higher CD4 nadir. Finally, it should be noted that we are in agreement with Mani et al in that in our letter we state that patients were on both protease inhibitor (PI) and non-PI antiretroviral (ARV) regimens and that there did not seem to be an association of persistent KS with either regimen.
